

# PATENT COOPERATION TREATY

JIP3

From the INTERNATIONAL SEARCHING AUTHORITY

To:  
G.E. EHRLICH (1995) LTD.  
G. E. EHRLICH (1995) LTD.  
11 MENACHEM BEGIN STREET  
RAMAT GAN, ISRAEL 52 521

**RECEIVED**  
**16 JUL 2004**  
FILE No. **26507**  
G.E. EHRLICH (1995)

**PCT**

INVITATION TO PAY ADDITIONAL FEES

(PCT Article 17(3)(a) and Rule 40.1)

Date of Mailing  
(day/month/year) **02 JUL 2004**

Applicant's or agent's file reference

26507

**PAYMENT DUE**

within 15 days  
from the above date of mailing

International application No.

PCT/IL03/00723

International filing date

(day/month/year) 02 September 2003 (02.09.2003)

Applicant

YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW

**1. This International Searching Authority**

(i) considers that there are 40 (number of) inventions claimed in the international application covered by the claims indicated below/on an extra sheet:  
Please See Continuation Sheet

and it considers that the international application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated below/on an extra sheet:  
Please See Continuation Sheet

(ii) ☐ has carried out a partial international search (see Annex) ☒ will establish the international search report on those parts of the international application which relate to the invention first mentioned in claims Nos.: 1-45, directed to a nucleic acid of SEQ ID NO:1 encoding SEQ ID NO:2

(iii) will establish the international search report on the other parts of the international application only if, and to the extent to which, additional fees are paid.

**2. The applicant is hereby invited, within the time limit indicated above, to pay the amount indicated below:**

<u>\$210.00</u>	X <u>39</u>	= <u>\$8,190.00</u>
Fee additional per invention	number of additional inventions	total amount of additional fees

The applicant is informed that, according to Rule 40.2(c), the payment of any additional fee may be made under protest, i.e., a reasoned statement to the effect that the international application complies with the requirement of unity of invention or that the amount of the required additional fee is excessive.

3. ☐ Claim(s) Nos. \_\_\_\_\_ have been found to be unsearchable under Article 17(2)(b) because of defects under Article 17(2)(a) and therefore have not been included with any invention.

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Cynthia Collins

Telephone No. (703) 308-0196

*Janice Ford*  
*for*

## INVITATION TO PAY ADDITIONAL FEES

International application No.  
PCT/IL03/00723

This International Search Authority has found 40 inventions claimed in the International Application covered by the claims indicated below:

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I-VI, claim(s) 1-45, drawn to an isolated nucleic acid, a cell, an organism, and a method of isolating a gene. (Group I is directed to a nucleic acid of SEQ ID NO:1 encoding SEQ ID NO:2, Group II is directed to a nucleic acid of SEQ ID NO:5, Group III is directed to a nucleic acid of SEQ ID NO:6, Group IV is directed to a nucleic acid of SEQ ID NO:34 encoding SEQ ID NO:35, Group V is directed to a nucleic acid of SEQ ID NO:39, Group VI is directed to a nucleic acid of SEQ ID NO:40)

Group VII-XII, claim(s) 46-50, 53, 56-60, 63, 66-70, 73 and 76-77, drawn to an isolated polypeptide, a method of using a polypeptide to prevent protein aggregation, and a method of isolating a protein. (Group VII is directed to a protein of SEQ ID NO:2 encoded by SEQ ID NO:1, Group VIII is directed to a protein encoded by SEQ ID NO:5, Group IX is directed to a protein encoded by SEQ ID NO:6, Group X is directed to a protein of SEQ ID NO:35 encoded by SEQ ID NO:34, Group XI is directed to a protein encoded by SEQ ID NO:39, Group XII is directed to a protein encoded by SEQ ID NO:40)

Group XIII, claim(s) 51-52, 61-62 and 71-72, drawn to an antibody and a method of using an antibody to isolate a gene.

Group XIV, claim(s) 54, 64 and 74, drawn to a method of using a polypeptide to de-aggregate protein.

Group XV, claim(s) 55, 65 and 75, drawn to a method of using a polypeptide to stabilize a protein against denaturing conditions.

Group XVI, claim(s) 78, drawn to a method of isolating a gene.

Group XVII, claim(s) 79, drawn to a method of isolating a gene.

Group XVIII, claim(s) 80, drawn to a method of isolating a nucleic acid.

Group XIX, claim(s) 81, drawn to a method of identifying a nucleic acid.

Group XX, claim(s) 82, drawn to a method of isolating a nucleic acid.

Group XXI, claim(s) 83, drawn to a method of isolating a protein.

Group XXII, claim(s) 84-87, drawn to a fusion protein.

Group XXIII, claim(s) 88, drawn to a method of immunization.

Group XXIV, claim(s) 89, drawn to a method of protecting an enzyme preparation from reduction in enzymatic activity.

Group XXV, claim(s) 90, drawn to a method of repairing at least a portion of lost enzymatic activity of an enzyme preparation.

Group XXVI, claim(s) 91, drawn to a method of administering a polypeptide to an animal having an immune system.

Group XXVII, claim(s) 92-94, drawn to a transgenic plant and a method of engineering a plant.

Group XXVIII, claim(s) 95, drawn to a method of increasing cell migration.

Group XXIX, claim(s) 96, drawn to a method of accelerating wound healing.

Group XXX, claim(s) 97, drawn to a method of inducing wound healing.

Group XXXI, claim(s) 98, drawn to a method of strengthening hair, nail or skin.

Group XXXII, claim(s) 99, drawn to a method of grooming the hair, nail or skin.

Group XXXIII, claim(s) 100-102, drawn to a pharmaceutical composition.

Group XXXIV, claim(s) 103-104, drawn to a method of isolating a protein.

Group XXXV, claim(s) 105-106, drawn to a method of treating a disease.

INVITATION TO PAY ADDITIONAL FEES

International application No.  
PCT/IL03/00723

Group XXXVI, claim(s) 107-108, drawn to a method of increasing a binding avidity of a binding molecule.

Group XXXVII, claim(s) 109-113, drawn to a hetero complex.

Group XXXVIII, claim(s) 114-129, drawn to an isolated protein.

Group XXXIX, claim(s) 130, drawn to a method of increasing a specific activity of a protein.

Group XL, claim(s) 131, drawn to a method of increasing a specific activity of a protein.

1. This International Searching Authority considers that the international application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated below:

The inventions listed as Groups I-XL do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The technical feature linking Groups I-XL is a boiling stable protein. However, a boiling stable protein is obvious or anticipated over PELAH et al. (Tree Physiology, 1995, Vol. 15, pages 673-678). Therefore, the technical feature linking the inventions of Groups I-XL does not constitute a special technical feature as defined by PCT Rule 13.2, because it does not define a contribution over the prior art. Furthermore, the special technical feature of each group of invention is the particular product and/or the particular method of making and/or using that product as set forth in the claims, as the products of groups I-XIII, XXII, XXVII, XXXIII, XXXVII and XXXVIII are different from each other, as are the methods of groups I-XXI, XXIII-XXXII, XXXIV-XXXVI, XXXIX and XL.